Related Experiment Video
Updated: Feb 1, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Cancer Neoantigens
Ton N Schumacher1,2, Wouter Scheper1,2, Pia Kvistborg1
1Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; email: t.schumacher@nki.nl , p.kvistborg@nki.nl.
Abstract:
Malignant transformation of cells depends on accumulation of DNA damage. Over the past years we have learned that the T cell-based immune system frequently responds to the neoantigens that arise as a consequence of this DNA damage. Furthermore, recognition of neoantigens appears an important driver of the clinical activity of both T cell checkpoint blockade and adoptive T cell therapy as cancer immunotherapies. Here we review the evidence for the relevance of cancer neoantigens in tumor control and the biological properties of these antigens. We discuss recent technological advances utilized to identify neoantigens, and the T cells that recognize them, in individual patients. Finally, we discuss strategies that can be employed to exploit cancer neoantigens in clinical interventions.
Insights
Cancer cells develop DNA damage, leading to neoantigens recognized by T cells. This immune response is crucial for cancer immunotherapies like checkpoint blockade and adoptive T cell therapy, driving tumor control.
Area of Science:
- Immunology and Cancer Biology
- Molecular Oncology
- Genetics and Genomics
Background:
- Malignant cellular transformation is linked to accumulating DNA damage.
- The T cell immune system can recognize neoantigens arising from DNA damage.
- Neoantigen recognition is a key factor in the efficacy of cancer immunotherapies.
Purpose of the Study:
- To review the significance of cancer neoantigens in tumor control.
- To discuss the biological characteristics of cancer neoantigens.
- To explore strategies for leveraging neoantigens in clinical cancer treatment.
Main Methods:
- Review of existing scientific literature and evidence.
- Discussion of recent technological advancements in neoantigen identification.
- Analysis of T cell responses to patient-specific neoantigens.
Main Results:
- Evidence supports the critical role of cancer neoantigens in mediating tumor control.
- Technological advances enable precise identification of neoantigens and cognate T cells in individual patients.
- Understanding neoantigen properties is essential for developing effective immunotherapies.
Conclusions:
- Cancer neoantigens are pivotal in the host immune response against tumors.
- Targeting neoantigens holds significant promise for advancing cancer immunotherapy.
- Future clinical interventions can be strategically designed to exploit cancer neoantigens.
Related Concept Videos
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
Cancer Prevention
Some...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...

